Issues and practices in multiple sclerosis (Q30751454)

26 June 2017

1 reference

title

Issues and practices in multiple sclerosis (English)

1 reference

26 June 2017

0 references

1

Jack S Burks

0 references

author name string

Barry G Arnason

2

1 reference

26 June 2017

Patricia K Coyle

3

1 reference

26 June 2017

Corey C Ford

4

1 reference

26 June 2017

Avertano Noronha

5

1 reference

26 June 2017

Kottil W Rammohan

6

1 reference

26 June 2017

publication date

1 December 2002

1 reference

Neurorehabilitation and Neural Repair

26 June 2017

published in

1 reference

26 June 2017

volume

16

1 reference

26 June 2017

issue

4

1 reference

26 June 2017

page(s)

307-320

1 reference

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

MRI dynamics of brain and spinal cord in progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Pathogenesis of tissue injury in MS lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

The genetic epidemiology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

The genetics of multiple sclerosis. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Multiple sclerosis among the United Kingdom-born children of immigrants from the West Indies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Varicella zoster virus and multiple sclerosis in a Hutterite population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Gender differences in age effect on brain atrophy measured by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154596830201600401

10.1177/154596830201600401

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference